Actinomycin D

DRUG3 trials

Sponsors

Weiguo Lv, H. Lee Moffitt Cancer Center and Research Institute, University of Birmingham

Conditions

Gestational Trophoblastic NeoplasmsRhabdomyosarcoma

Phase 1

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

RecruitingNCT04625907

University of BirminghamRhabdomyosarcoma

Start: 2020-09-17End: 2030-06-30Target: 1672Updated: 2024-05-23

Phase 2

Evolutionary Therapy for Rhabdomyosarcoma

Active, not recruitingNCT04388839

H. Lee Moffitt Cancer Center and Research InstituteRhabdomyosarcoma

Start: 2020-12-29End: 2027-08-31Updated: 2025-11-26

Phase 3

Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

RecruitingNCT02639650

Weiguo LvGestational Trophoblastic Neoplasms

Start: 2016-03-01End: 2026-03-01Target: 214Updated: 2022-06-03

Related Papers

Determining the recommended phase 2 dose (RP2D) of dose-intense irinotecan combined with IVA chemotherapy (I <sub>R</sub> IVA) in newly diagnosed very high risk rhabdomyosarcoma: A phase Ib study within the EpSSG Frontline and Relapsed Rhabdomyosarcoma study (FaR-RMS).

Journal of Clinical Oncology2025-05-281 citations

A dual readout embryonic zebrafish xenograft model of rhabdomyosarcoma to assess clinically relevant multi-receptor tyrosine kinase inhibitors

Frontiers in Oncology2025-05-212 citations

Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer

BMJ Open2024-12-017 citations

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study

Clinical Cancer Research2023-08-2228 citations

Biological Role and Clinical Implications of <i>MYOD1<sup>L122R</sup></i> Mutation in Rhabdomyosarcoma.

2023-03-0710 citations